Clinical Trial Search

Primary: Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12 — 0.48; 0.72 milligram/gram (mg/g) — p=<0.001

Primary: Count and Percentage of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events (AEs) and Laboratory Abnormalities Among Participants Who Receive at…

Primary: Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2 — 12 Participants

Primary: Oral Clearance (CL/F) (Cohort 1 Only) — 28.4 (L/hr)

Primary: Height Standard Deviation Score — -2.52; -1.57; -1.19; -1.09 standard deviation score

Primary: Effective Dose for 50% of Patients for Succesful Intubation and Subsequent Extubation in Case of Planned Extubation After INSURE Procedure — 0.792; 0.713; 1.350 mg/kg

Primary: Change in Innate Immune Signatures Post-vaccine Dose — 1.6801; 2.096; -0.5609; -1.1284 Normalized Enrichment Score (NES)

Primary: Total Corneal Fluorescein Staining — 7.35; 7.25; 7.12 score on a scale

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 75 Participants

Primary: Percentage of Low Transfusion Burden (LTB) Participants With Modified Erythroid Response (mHI-E) — 0; 0; 66.7; 100 Percentage of participants

Primary: Overall Response Rate — 0; 2 Participants

Primary: Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24) — 16.7; 32.0; 46.0; 12.0 percentage of…

Primary: Progression Free Survival (PFS) Per RECIST 1.1 — 9.13 Months

Primary: Number of Participants With Dose Limiting Toxicity — 0 Participants

Primary: Number of Live Births — 3; 1 live births